Search results for "Liver Cancer"

showing 10 items of 172 documents

Does access to care play a role in liver cancer survival? The ten-year (2006–2015) experience from a population-based cancer registry in Southern Ita…

2021

Abstract Background Hepatocellular carcinoma (HCC) is the most frequent primary invasive cancer of the liver. During the last decade, the epidemiology of HCC has been continuously changing in developed countries, due to more effective primary prevention and to successful treatment of virus-related liver diseases. The study aims to examine survival by level of access to care in patients with HCC, for all patients combined and by age. Methods We included 2018 adult patients (15–99 years) diagnosed with a primary liver tumour, registered in the Palermo Province Cancer Registry during 2006–2015, and followed-up to 30 October 2019. We obtained a proxy measure of access to care by linking each re…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularAdolescentContext (language use)access to care cancer registries liver cancer public health survival Adolescent AdultAge Distribution Aged Aged 80 and over Carcinoma Hepatocellular Decision Making Organizational Decision Support Techniques Female Follow-Up Studies Health Services Accessibility Health Services Needs and Demand Humans Italy Liver Neoplasms Male Middle Aged Registries Survival Analysis Young AdultSettore MED/42 - Igiene Generale E Applicatalcsh:RC254-282survivalHealth Services AccessibilityDecision Support Techniquesliver cancerYoung AdultAge DistributionInternal medicineHealth careEpidemiologyGeneticsmedicineHumansRegistriesDecision Making OrganizationalAgedAged 80 and overaccess to careHealth Services Needs and Demandbusiness.industryPublic healthLiver Neoplasmspublic healthMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSurvival AnalysisCancer registryItalyOncologycancer registriesHepatocellular carcinomaAmbulatoryFemaleLiver cancerbusinessFollow-Up StudiesResearch ArticleBMC Cancer
researchProduct

Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis

2021

Development of primary liver cancer is a multistage process. Detailed understanding of sequential epigenetic alterations is largely missing. Here, we performed Infinium Human Methylation 450k BeadChips and RNA-Seq analyses for genome-wide methylome and transcriptome profiling of cirrhotic liver (n = 7), low- (n = 4) and high-grade (n = 9) dysplastic lesions, and early (n = 5) and progressed (n = 3) hepatocellular carcinomas (HCC) synchronously detected in 8 patients with HCC with chronic hepatitis B infection. Integrative analyses of epigenetically driven molecular changes were identified and validated in 2 independent cohorts comprising 887 HCCs. Mitochondrial DNA sequencing was further em…

AdultMaleMitochondrial DNACarcinoma HepatocellularCirrhosisMolecular biologyCarcinogenesisBiologyEpigenesis GeneticHepatitis B ChronicmedicineHumansEpigeneticsAgedHepatologyGene Expression ProfilingLiver NeoplasmsDNA NeoplasmGeneral MedicineMethylationDNA MethylationMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticOncologyApoptosisDNA methylationCancer researchEpigeneticsCalmodulin-Binding ProteinsFemaleLiver cancerLiver cancerResearch ArticleJCI Insight
researchProduct

Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience

2010

AdultMalePediatricsmedicine.medical_specialtyCarcinoma HepatocellularIron OverloadCirrhosisThalassemiaCarcinomaHumansMedicineAgedbusiness.industryLiver NeoplasmsTransfusion ReactionCancerHematologyHepatitis CHepatitis C ChronicMiddle AgedPrognosismedicine.diseaseSurgeryHemoglobinopathyHepatocellular carcinomaThalassemiaThalassaemia hepatocellular carcinoma iron overload cirrhosis hepatitis CFemalebusinessLiver cancer
researchProduct

Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.

2016

Background & Aims GALAD and BALAD-2 are statistical models for estimating the likelihood of the presence of hepatocellular carcinoma (HCC) in individual patients with chronic liver disease and the survival of patients with HCC, respectively. Both models use objective measures, particularly the serum markers α-fetoprotein (AFP), AFP-L3, and des-γ-carboxyprothrombin. We aimed to validate these models in an international cohort of patients with HCC and assess their clinical performance. Methods We collected data on cancer diagnosis and outcomes of 6834 patients (2430 with HCC and 4404 with chronic liver disease) recruited from Germany, Japan, and Hong Kong. We also collected data from 229 pati…

AdultMalemedicine.medical_specialtyAsiaCarcinoma HepatocellularMedizinChronic liver diseaseGastroenterologyDecision Support TechniquesCohort Studies03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansneoplasmsSurvival analysisAgedHepatologybusiness.industryDiagnostic Tests RoutineLiver NeoplasmsGastroenterologyCancerMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesEurope030220 oncology & carcinogenesisHepatocellular carcinomaCohortAdenocarcinoma030211 gastroenterology & hepatologyFemalebusinessLiver cancerBiomarkersCohort studyClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?

2018

BACKGROUND & AIMS Portal vein tumour thrombosis (PVTT) has a significant impact on the prognosis of patients with hepatocellular carcinoma (HCC). The degree of PVTT varies from sub-/segmental invasion to complete occlusion of the main trunk. Aim of this study was to evaluate whether the degree of PVTT correlates with prognosis. METHODS A total of 1317 patients with HCC treated at our tertiary referral centre between January 2005 and December 2016 were included. PVTT was diagnosed by contrast-enhanced computed tomography or magnetic resonance imaging. The extent of PVTT was documented according to the Liver Cancer Study Group of Japan classification: Vp0 = no PVTT, Vp1 = segmental portal vei…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularAdolescentvirusesPortal veinYoung Adult03 medical and health sciences0302 clinical medicineGermanyComplete occlusionHepatectomyHumansMedicineIn patientAgedRetrospective StudiesAged 80 and overVenous ThrombosisHepatologyLeft portal veinmedicine.diagnostic_testPortal Veinbusiness.industryLiver NeoplasmsMagnetic resonance imagingMiddle AgedPrognosismedicine.diseaseSurvival AnalysisThrombosisSurvival Rate030220 oncology & carcinogenesisHepatocellular carcinomaFemale030211 gastroenterology & hepatologyRadiologybusinessLiver cancerLiver International
researchProduct

Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

2015

OBJECTIVES:The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B) includes a heterogeneous population of patients with hepatocellular carcinoma (HCC). Recently, in order to facilitate treatment decisions, a panel of experts proposed to subclassify BCLC B patients. In this study, we aimed to assess the prognostic capability of the BCLC B stage reclassification in a large cohort of patients with untreated HCC managed by the Italian Liver Cancer Group.METHODS:We assessed the prognosis of 269 untreated HCC patients observed in the period 1987-2012 who were reclassified according to the proposed subclassification of the BCLC B stage from stage B1 to stage B4. We evaluated and compa…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularPrognosiAdult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Young Adult; GastroenterologyGastroenterologyIntermediate stage03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineCarcinoma80 and overHumansProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overHepatologybusiness.industryMedicine (all)Settore MED/09 - MEDICINA INTERNACarcinomaLiver NeoplasmsGastroenterologyHepatocellularMiddle Agedmedicine.diseasePrognosisProspective StudieLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm stagingFemaleLiver cancerbusinessHuman
researchProduct

Mini-Invasive Approach Contributes to Expand the Indication for Liver Resection for Hepatocellular Carcinoma Without Increasing the Incidence of Post…

2016

Liver resection (LR) for hepatocellular carcinoma (HCC) is the best alternative option for increasing the survival of many patients with intermediate or advanced stages of the Barcelona Clinic Liver Cancer staging classification. Mini-invasive approach may play a positive role in treating a tumor rising almost exclusively in a diseased liver.A prospectively collected database was retrospectively reviewed for 167 consecutive patients who underwent LR between 1999 and 2015.A total of 38 LRs were performed from 1999 to 2009 (Period I), and 129 between 2010 and 2015 (Period II). Laparoscopic procedures increased from 5.3% to 38.1%. Not undergoing laparoscopic LR increased length of stay, and Cl…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularSingle Center03 medical and health sciences0302 clinical medicinePostoperative ComplicationsCarcinomaMedicineHepatectomyHumansLaparoscopyAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryIncidence (epidemiology)IncidenceLiver NeoplasmsRetrospective cohort studyPerioperativeMiddle Agedmedicine.diseaseSurgeryTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologySurgeryFemaleLaparoscopybusinessLiver cancerLiver Failure
researchProduct

Five-Year Survival After Monotherapy for Hepatocellular Carcinoma in the Setting of Cirrhosis

2008

The purpose of this study was to evaluate the long-term results with monotherapy for hepatocellular carcinoma (HCC) in the setting of cirrhosis. We reviewed data of 14 patients who survived for at least 5 years after performance of liver resection (n = 1), transarterial chemoembolization (TACE, n = 3), or liver transplantation (OLT, n = 19). Eight patients were within the Milan criteria, whereas the remaining 6 were beyond the criteria. Tumor stages according to the UICC were I (n = 8), II (n = 5), and IIIA (n = 1). Vascular invasion was not detected in any patient. The HCCs recurred in 2 patients, at 81 and 48 months' posttransplant. Sites of recurrence were the intrathoracic lymph nodes i…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentMedizinMilan criteriaLiver transplantationGastroenterologyInternal medicinemedicineCarcinomaHumansSurvivorsChemoembolization TherapeuticSurvival rateAgedTransplantationbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseLiver TransplantationSurgerySurvival RateTransplantationHepatocellular carcinomaFemaleSurgeryalpha-FetoproteinsNeoplasm Recurrence LocalbusinessLiver cancerFollow-Up StudiesTransplantation Proceedings
researchProduct

Living Donor Liver Transplantation for Hepatocellular Carcinoma in Patients Exceeding the UCSF Criteria

2008

Abstract Background Living donor liver transplantation (LDLT) represents an alternative to expand the organ pool for adult patients with hepatocellular carcinoma (HCC) and end-stage liver disease. The purpose of this study was to demonstrate our institutional experience using criteria exceeding those of the University of California San Francisco (UCSF). Patients and Methods Between September 1998 and December 2006, 22 LDLTs were performed for HCC among patients exceeding the UCSF criteria. Results There were 17 men and 5 women of median age 55 years. Multifocal tumors were present in 19 of 22 patients. Tumor grading was: grade I (n = 8), grade II (n = 10), and grade III (n = 4). Microvascul…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentMedizinLiver transplantationGastroenterologyDisease-Free SurvivalLiver diseaseInternal medicineLiving DonorsTumor GradingHumansMedicineIn patientSurvivorsNeoplasm StagingTransplantationbusiness.industryPatient SelectionLiver NeoplasmsCancerMiddle Agedmedicine.diseaseLiver TransplantationSurgerySurvival RateHepatocellular carcinomaFemaleSurgerybusinessLiver cancerLiving donor liver transplantationTransplantation Proceedings
researchProduct

A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia

2013

Objective— In familial hypobetalipoproteinemia, fatty liver is a characteristic feature, and there are several reports of associated cirrhosis and hepatocarcinoma. We investigated a large kindred in which low-density lipoprotein cholesterol, fatty liver, and hepatocarcinoma displayed an autosomal dominant pattern of inheritance. Approach and Results— The proband was a 25-year-old female with low plasma cholesterol and hepatic steatosis. Low plasma levels of total cholesterol and fatty liver were observed in 10 more family members; 1 member was affected by liver cirrhosis, and 4 more subjects died of either hepatocarcinoma or carcinoma on cirrhosis. To identify the causal mutation in this f…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BNonsense mutationBiologyArticlehypobetaliproteinemia type 1Hypobetalipoproteinemiasexome fatty liver hypobetalipoproteinemia familial 2Young Adultsymbols.namesakeInternal medicinemedicineHumansExomeHEPATOCELLULAR CARCINOMAExomeExome sequencingApolipoproteins Bfatty liverFamily HealthGeneticsSanger sequencingLiver NeoplasmsFatty liverMiddle AgedHEPATOCELLULAR CARCINOMA; exome; fatty liver; hypobetaliproteinemia type 1medicine.diseasePedigreeFatty LiverHypocholesterolemiaCholesterolEndocrinologyCodon Nonsensebiology.proteinsymbolsFemaleCardiology and Cardiovascular MedicineLiver cancerexomeArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct